Alemtuzumab versus anti‐thymocyte globulin in kidney transplant recipients receiving a rapid steroid withdrawal regimen
Fuente:
Wiley Open Access
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2024
|
| Subjects: | |
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1867017211141423104 |
|---|---|
| author | Rachel A. Rikard Laura M. Chargualaf Carolyn Coulter Eric T. Weimer John L. Schmitz Elizabeth S. Kotzen Alyson Prom Alexander H. Toledo Kristen R. Szempruch |
| author_facet | Rachel A. Rikard Laura M. Chargualaf Carolyn Coulter Eric T. Weimer John L. Schmitz Elizabeth S. Kotzen Alyson Prom Alexander H. Toledo Kristen R. Szempruch Rachel A. Rikard Laura M. Chargualaf Carolyn Coulter Eric T. Weimer John L. Schmitz Elizabeth S. Kotzen Alyson Prom Alexander H. Toledo Kristen R. Szempruch |
| collection | Wiley Open Access |
| contents | Alemtuzumab versus anti‐thymocyte globulin in kidney transplant recipients receiving a rapid steroid withdrawal regimen Rachel A. Rikard Laura M. Chargualaf Carolyn Coulter Eric T. Weimer John L. Schmitz Elizabeth S. Kotzen Alyson Prom Alexander H. Toledo Kristen R. Szempruch Clinical Transplantation AbstractIntroductionIn kidney transplant recipients (KTRs), steroid‐free maintenance regimens are used to minimize the negative impact of steroid use. Studies comparing alemtuzumab (ALZ) and anti‐thymocyte globulin (ATG) with rapid steroid withdrawal are limited. The aim of this study was to assess a composite outcome of incidence of de novo donor specific antibodies (dnDSAs), biopsy proven rejection (BPAR), graft failure, or death in KTRs receiving ALZ or ATG with a steroid‐free maintenance regimen.MethodsA single‐center, retrospective cohort study was conducted in adult KTRs who underwent rapid steroid withdrawal. There were two cohorts, KTRs who received induction with ALZ compared to ATG. The primary composite outcome was incidence of dnDSAs, BPAR, graft failure, or death. Secondary outcomes included renal function, cytomegalovirus (CMV) and BK viremia, and leukopenia.ResultsTwo hundred twenty‐five KTRs were included where 146 received ALZ and 79 received ATG. The Cox proportional hazard of the primary composite outcome in the ALZ compared to ATG group was not significant (unadjusted model HR 1.37, 95% CI .74–2.55). Individual incidences of composite outcome were similar. There was a difference in estimated glomerular filtration rate at 12 months post‐transplant (55.7 vs. 62.3 mL/min/1.73m2, p = .03) and leukopenia at 3 months (3.7 vs. 4.2 × 109/L, p = .03). Other secondary outcomes were similar.ConclusionsThere was no difference in composite outcome for dnDSAs, BPAR, graft failure, and death. 10.1111/ctr.15244 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| doi_str_mv | 10.1111/ctr.15244 |
| format | Artículo Open Access |
| id | wiley_oa_10_1111_ctr_15244 |
| institution | Wiley Open Access |
| license_str_mv | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| publishDate | 2024 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Alemtuzumab versus anti‐thymocyte globulin in kidney transplant recipients receiving a rapid steroid withdrawal regimen Rachel A. Rikard Laura M. Chargualaf Carolyn Coulter Eric T. Weimer John L. Schmitz Elizabeth S. Kotzen Alyson Prom Alexander H. Toledo Kristen R. Szempruch Clinical Transplantation Alemtuzumab versus anti‐thymocyte globulin in kidney transplant recipients receiving a rapid steroid withdrawal regimen Rachel A. Rikard Laura M. Chargualaf Carolyn Coulter Eric T. Weimer John L. Schmitz Elizabeth S. Kotzen Alyson Prom Alexander H. Toledo Kristen R. Szempruch Clinical Transplantation AbstractIntroductionIn kidney transplant recipients (KTRs), steroid‐free maintenance regimens are used to minimize the negative impact of steroid use. Studies comparing alemtuzumab (ALZ) and anti‐thymocyte globulin (ATG) with rapid steroid withdrawal are limited. The aim of this study was to assess a composite outcome of incidence of de novo donor specific antibodies (dnDSAs), biopsy proven rejection (BPAR), graft failure, or death in KTRs receiving ALZ or ATG with a steroid‐free maintenance regimen.MethodsA single‐center, retrospective cohort study was conducted in adult KTRs who underwent rapid steroid withdrawal. There were two cohorts, KTRs who received induction with ALZ compared to ATG. The primary composite outcome was incidence of dnDSAs, BPAR, graft failure, or death. Secondary outcomes included renal function, cytomegalovirus (CMV) and BK viremia, and leukopenia.ResultsTwo hundred twenty‐five KTRs were included where 146 received ALZ and 79 received ATG. The Cox proportional hazard of the primary composite outcome in the ALZ compared to ATG group was not significant (unadjusted model HR 1.37, 95% CI .74–2.55). Individual incidences of composite outcome were similar. There was a difference in estimated glomerular filtration rate at 12 months post‐transplant (55.7 vs. 62.3 mL/min/1.73m2, p = .03) and leukopenia at 3 months (3.7 vs. 4.2 × 109/L, p = .03). Other secondary outcomes were similar.ConclusionsThere was no difference in composite outcome for dnDSAs, BPAR, graft failure, and death. 10.1111/ctr.15244 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| title | Alemtuzumab versus anti‐thymocyte globulin in kidney transplant recipients receiving a rapid steroid withdrawal regimen |
| topic | Clinical Transplantation |
| url | https://onlinelibrary.wiley.com/doi/10.1111/ctr.15244 |